Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration

Condition(s) studied

Investigational drug(s) / intervention(s)

No intervention.: No intervention. Evaluate the automated AMD screening software.

Study summary

The purpose of this study is to perform a pivotal trial of iPredict, an automated AI-based system for early diagnosis and prediction of late AMD in primary care and ophthalmology settings. Patients will be invited to participate in this study by having non-dilated photos of their eyes taken by an FDA approved fundus camera (DRSPlus from Centervue Inc., CA), at their primary care doctor's office or general ophthalmologist office. The photos will then be transmitted securely and analyzed by computer in the cloud (telemedicine features). Sufficient accuracy of the automatic system has been established compared to the ophthalmologist's diagnosis. In this study, we aim to validate the system against the prospectively taken OCT image and color fundus images.

Eligibility

Primary outcome measure(s)

• Referable and non-referable AMD. And Predict the Incidence of AMD in 1 year or 2-year. — 1 year or 2-year
  Referable and non-referable AMD. And Predict the Incidence of AMD in 1 year or 2-year.

Trial sites (1)

More iHealthScreen Inc trials in the USA

Other trials for the same condition